Clinical trials: Diabetic Macular Oedema
Diabetic Retinopathy
Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema
To assess the safety and efficacy of two subthreshold parameters (5% and 15% duty cycle (DC)) compared to standard ETDRS (early treatment of diabetic retinopathy study) continuous wave (CW) laser
- Trial name
- NCT03571659
- Testing
- Laser
- Volunteers
- 32 people
- Sponsor
- L.V. Prasad Eye Institute
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China.
- Conditions
- Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT06439576
- Testing
- Faricimab
- Where
- 41 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Diffuse Diabetic Macular Edema
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.
- Trial name
- NCT00886808
- Testing
- iCo-007 Intravitreal Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- iCo Therapeutics Inc.
Diabetic Macular Edema
MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)
The objective of this study is to investigate if the drug ranibizumab administrated by microdose injection into the eye is safe and effective to treat diabetic macular edema.
- Trial name
- MINIMA-2 (NCT01112085)
- Testing
- Ranibizumab 0.05mg, Ranibizumab 0.5mg
- Where
- 6 sites in Argentina, Mexico
- Volunteers
- 72 people
- Sponsor
- Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03666923
- Testing
- THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with…
- Trial name
- NCT00936520
- Testing
- SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Diffuse Diabetic Macular Edema
Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.
- Trial name
- NCT00571142
- Testing
- Bevacizumab + Pars plana vitrectomy
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Macular Edema
Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema
This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema.
- Trial name
- NCT04772105
- Testing
- 2.5mg of BAT5906, 4.0mg of BAT5906
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Bio-Thera Solutions
Age - Related Macular Degeneration (AMD), Diabetic Macular Edema
Wide Field OCTA in Ocular Diseases
The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function.
- Conditions
- Age - Related Macular Degeneration (AMD), Diabetic Macular Edema, Diabetic Retinopathy, Myopia
- Trial name
- WOOD-2025 (NCT07298174)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Diabetic Retinopathy
High Blood Pressure and Sleep Apnea in Diabetic Macular Edema
Macular edema remains a major cause of vision impairment in diabetic patients. Its pathogenesis is multifactorial and incompletely understood.
- Trial name
- OMHADIA (NCT00970723)
- Testing
- high blood pressure treatment, sleep apnea treatment, diabetic macular edema treatment
- Where
- 5 sites in France
- Volunteers
- 86 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetic Retinopathy, Macular Degeneration
Diabetic Retinopathy and Visual Function Study
The purpose of this study is to evaluate possible mechanisms of central visual loss in patients with diabetes mellitus. The visual loss of interest to be investigated is that associated with macular edema (prior to and following…
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Vision, Subnormal
- Trial name
- NCT00001346
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Eye Institute (NEI)
Macular Edema
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
- Trial name
- NCT02188173
- Testing
- dexamethasone 700 ㎍ intravitreal implant
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Allergan
Diabetic Retinopathy, Diabetic Eye Problems
Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision…
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT03112005
- Testing
- Color fundus photography, Mydriatic Agent
- Where
- United States
- Volunteers
- 942 people
- Sponsor
- Eyenuk, Inc.
Diabetic Retinopathy
PST/Laser v. Laser Alone for CSME
Prospective randomized clinical trial comparing Laser Alone v. Laser and posterior sub-tenon injection of triamcinolone acetonide for primary and refractory clinically significant macular edema.
- Trial name
- NCT00229918
- Testing
- triamcinolone acetonide
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Edward Hines Jr. VA Hospital
Diabetes Mellitus, Diabetic Retinopathy
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
This study will evaluate the safety and efficacy of AG-014699 in diabetic patients
- Trial name
- NCT00457470
- Testing
- AG-014699
- Sponsor
- Pfizer
Diabetic Macular Edema
Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema
This is a 3-year randomized, dose masked, three-arm controlled, pilot study to evaluate the safety and efficacy of the intravitreal FA implants (0.59mg and 2.1mg), when compared to laser photocoagulation in the treatment of…
- Trial name
- NCT00576459
- Testing
- 0.59 mg fluocinolone acetonide intravitreal implant, 2.1 mg fluocinolone acetonide intravitreal implant, standard of care laser photocoagulation
- Where
- 2 sites in China, India
- Volunteers
- 40 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetic Macular Edema
Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
Diabetic macular oedema (DME) is the main cause of visual impairment (or visual acuity) in patients with diabetic retinopathy, as it leads to progressive thickening of the retina, which in the long term leads to progressive death…
- Trial name
- EMMA (NCT04910503)
- Testing
- Dexamethasone intravitreal implant, Fluocinolone Acetonide Intravitreal Implant
- Where
- France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetic Macular Edema, Diabetic Retinopathy
Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema
Diabetic macular edema (DME) is an important cause of central vision impairment among people with diabetic retinopathy (DR), which can have a significant adverse effect on daily activities and quality of life.
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic
- Trial name
- NCT04668703
- Testing
- Conbercept intravitreal injection
- Volunteers
- 40 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Diabetic Macular Edema
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis®…
- Trial name
- PRO-169 (NCT05217680)
- Testing
- Bevacizumab, Lucentis®
- Where
- Mexico
- Volunteers
- 509 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Diabetes Mellitus, Diabetic Macular Edema
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with diabetic macular edema (DME). This study will evaluate the percent change from baseline in excess central subfield thickness (CST) in the…
- Trial name
- VIDI (NCT02302079)
- Testing
- ASP8232, ranibizumab
- Where
- 21 sites in United States
- Volunteers
- 96 people
- Sponsor
- Astellas Pharma Europe B.V.